Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From PsychoGenics Inc.

Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas

Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.

Deals Business Strategies

Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena

Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.

Neurology Clinical Trials

Dainippon Lays Out R&D Table Ahead Of Latuda Challenges

Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.

Clinical Trials Innovation

Blonanserin On Course As First Atypical For Adolescent Schizophrenia In Japan

Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.

Japan Clinical Trials
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Transgenics
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
      • Genomics-Proteomics
UsernamePublicRestriction

Register